To amend sections 1751.12 and 1751.32 and to enact sections 3923.811 and 3959.21 of the Revised Code to prohibit certain health insurance cost-sharing practices.
SB207 would revise Ohio insurance law to restrict certain health plan cost-sharing practices and prescription drug benefit design practices. The bill amends existing provisions governing health insuring corporations and adds new sections applicable to sickness and accident insurers and pharmacy benefit managers. It requires cost-sharing amounts such as copayments, coinsurance, deductibles, and similar charges to be reasonable and, in most cases, capped at the annual federal cost-sharing limit used under the Affordable Care Act. It also prohibits insurers and health plans from designing coverage based on the availability or amount of prescription drug assistance, such as manufacturer copay assistance, and requires that amounts paid by or on behalf of an enrollee generally be counted toward cost-sharing obligations.
The bill includes several exceptions and coordination rules for high-deductible health plans linked to health savings accounts, catastrophic plans, preventive care, and certain brand-name drugs when a generic equivalent exists unless the prescriber determines the brand is medically necessary. It also bars lifetime maximums on basic health care services for health insuring corporations, while preserving some limits for supplemental inpatient hospital coverage. In addition, it expands annual reporting and certification requirements for health insuring corporations, sickness and accident insurers, and pharmacy benefit managers, including certifications of compliance with the new cost-sharing and benefit-design restrictions.
If enacted, SB207 would materially affect Ohio’s insurance code by imposing new substantive limits on how insurers and health insuring corporations structure member cost-sharing and prescription drug benefits, and by bringing pharmacy benefit managers under direct statutory compliance obligations tied to those limits. The bill would apply to health benefit plans delivered, issued, modified, or renewed on or after January 1, 2027, giving carriers and PBMs time to adjust plan design, claims processing, and compliance systems. It would also increase oversight by the Superintendent of Insurance through filing, review, and annual certification requirements.
The general sentiment reflected by the bill text is consumer-protection oriented, with a focus on reducing barriers to care and limiting practices that can increase out-of-pocket costs for patients. Because there are no committee transcripts or recorded votes provided, there is no documented debate or formal vote history in the supplied materials to indicate broader legislative support or opposition. The structure of the bill suggests an intent to align Ohio coverage rules with federal cost-sharing concepts while also addressing prescription drug affordability and copay assistance practices.
The main points of potential contention are likely to involve the scope of insurer and PBM regulation, the requirement to count third-party assistance toward cost-sharing, and the interaction with high-deductible health plans and health savings account eligibility. Insurers and pharmacy benefit managers may object to the administrative burden, pricing constraints, and possible effects on plan design or premiums, while patient advocates and supporters are likely to favor the bill’s limits on cost-sharing and prescription drug affordability barriers. The generic-drug exception and HSA-related carveouts indicate an effort to balance consumer protections with existing federal tax and benefit rules.
SB207 would amend Ohio’s insurance statutes governing health insuring corporations and sickness and accident insurers, and it would create new compliance duties for pharmacy benefit managers. It would require cost-sharing limits tied to federal ACA standards, prohibit benefit design decisions based on prescription drug assistance, bar lifetime maximums on basic health care services, and require annual compliance certifications and reporting to the Superintendent of Insurance. The bill would apply prospectively to plans issued, renewed, or modified on or after January 1, 2027, affecting insurers, PBMs, employers offering coverage, and enrollees in Ohio health benefit plans.
The bill appears generally favorable toward consumers and patients, with a policy goal of lowering out-of-pocket barriers and preventing insurers from structuring coverage around prescription assistance programs. No committee testimony or vote record was provided, so there is no direct evidence of bipartisan support, organized opposition, or amendment activity in the supplied materials. Based on the text alone, the bill is framed as a regulatory and affordability measure rather than a controversial benefit expansion.
Likely areas of contention include whether the new cost-sharing caps and prescription drug rules would increase premiums, reduce plan flexibility, or interfere with employer-sponsored benefit design. Another likely dispute is the requirement to count third-party prescription assistance toward an enrollee’s cost-sharing, which supporters may view as protecting patients but opponents may argue could undermine manufacturer assistance programs or plan cost controls. The bill’s exceptions for high-deductible health plans, catastrophic plans, and medically necessary brand drugs suggest lawmakers anticipated concerns about federal tax treatment, HSA compatibility, and clinical discretion.